Ranolazine Tablet, Film Coated, Extended Release
Product Images NDC 90096-151

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Ranolazine (NDC 90096-151). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zameer Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label 1000 mg (Image 3)

This is a description of Ranolazine extended-release tablets with a strength of 1000 mg. The tablets should be swallowed whole and not crushed, broken, or chewed. They should be stored at a temperature between 15°C to 30°C (59°F to 86°F). The package insert should be consulted for dosage and administration instructions. These tablets are distributed by Zameer Pharmaceuticals LLC and manufactured by Piramal Pharma Limited in India for Piramal Healthcare UK Ltd. It is important to keep this medication out of the reach of children and dispense it in a light-resistant and child-resistant container.*

FDA Label Image

Structure (Image 01)

FDA Label Image

Label 500 mg (R500mg)

This text provides information about Ranolazine, an extended-release tablet used for treating certain heart conditions. Each tablet contains 500 mg of ranolazine and should be swallowed whole without crushing, breaking, or chewing. The tablets should be stored at room temperature and kept out of reach of children in a light-resistant, child-resistant container. The manufacturing details and distribution information are also included in the text.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.